Etcembly

Curated by Signal

Provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy

Overview

Provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy. The platform utilizes machine learning to develop high-affinity TCRs with unprecedented speed and precision for cancer treatment.

Key facts

Founded: 2020
Headquarters: Harwell, United Kingdom
Stage: Sign up to view
Industry: Health Technology

Business model

1 product or service: Sign up to view

Contact

Email: Sign up to view
Phone: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

Stix
Provider of wellbeing support for kids through mindfulness app
Health TechnologyHayes, United Kingdom
Thermidor
Provider of temperature monitoring system for workplaces
Health TechnologyLondon, United Kingdom
Lymphoma Hub
Online information resource for healthcare professionals
Health TechnologyThames Ditton, United Kingdom

About Etcembly

What does Etcembly do?

Provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy.

Where is Etcembly headquartered?

Etcembly is headquartered in Harwell, United Kingdom.

When was Etcembly founded?

Etcembly was founded in 2020.

Which sector is Etcembly in?

Etcembly operates in Health Technology.

Who are Etcembly's competitors?

Companies similar to Etcembly include Stix, Thermidor, and Lymphoma Hub.